Pharmacosmos
pharmacosmos.com
Actively hiring
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
News
Pharmacosmos initiates phase III clinical trial of trilaciclib in limited-stage small cell lung cancer
Read more
Report
Pharmacosmos Group and G1 Therapeutics Announce Expiration of Hart-Scott-Rodino Waiting Period
--Pharmacosmos A/S, a leader in the development of innovative treatments for patients suffering from iron deficiency and iron deficiency anemia, and G1 Therapeutics, Inc., a commercial-stage oncology company focused on delivering next-generation therapies
Read more
Report
Pharmacosmos ventures into oncology and merges with G1 Therapeutics
Pharmacosmos will secure its second FDA-approved drug and first oncology therapy, G1 Therapeutics' Costela as part of the merger.
Read more
Report
Pharmacosmos Group to Acquire G1 Therapeutics
- Business Combination Expected to Provide Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC) Optimal Access to G1's COSELA (trilaciclib), the First and Only Proactive Multilineage Myeloprotection
Read more
Report
G1 Therapeutics To Be Acquired By Pharmacosmos For $7.15/shr In Cash
(RTTNews) - G1 Therapeutics, Inc. (GTHX) announced Wednesday an agreement to be acquired by Pharmacosmos A/S, through its U.S. subsidiary Pharmacosmos Therapeutics Inc., for $7.15 per share in cash. Following this news the shares are up 66% in the pre-mar
Read more
Report
Pharmacosmos Therapeutics Inc. established as a new specialty pharmaceutical company to bring recently approved treatment option to iron deficiency anemia patients
Read more
Report
Pharmacosmos l Images and Brand Guide
Kontainer PIM and DAM for sharing, editing, archiving, and integrating images, product information and brand guidelines - GDPR compliant marketing tool
Read more
Report